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ABSTRACT
Objectives: Tegaserod is effective, safe, and well-tolerated in
the treatment of patients with irritable bowel syndrome (IBS)
with constipation. The aim of this study was to assess, from
a payer perspective, the cost-effectiveness of tegaserod in the
treatment of IBS patients, based on the TEgaserod in NORdic
region (TENOR) trial data.
Methods: Female and male patients (Rome II criteria) were
randomized to receive tegaserod 6 mg b.i.d. or placebo for
12 weeks. Patients (247 tegaserod; 238 placebo) completed
the EuroQol EQ-5D questionnaire at baseline, Week 4,
and Week 12. A 12-week economic study was undertaken
to assess the incremental cost-effectiveness ratio (ICER) of
tegaserod in terms of cost per quality-adjusted life-year
(QALY) gained. Cost-effectiveness acceptability curves were
calculated toestimate the probability of tegaserod being
cost-effective at different benchmark values of cost per
QALY gained.
Results: By assuming a daily drug cost to payers of €2, €3,
and €4, the ICER of tegaserod ranges between €19,000 and
€38,000 per QALY gained, with the percentage of the boot-
strap estimates below the willingness to pay level of €50,000
per QALY gained ranging between 90% and 69%.
Conclusions: This study established directly from a random-
ized controlled clinical trial that tegaserod is cost-effective in
the treatment of non-D-IBS patients.
Keywords: clinical trial, constipation, irritable bowel syn-
drome, Nordic, quality of life, quality-adjusted life-years,
tegaserod, therapeutic.
Introduction
Irritable bowel syndrome (IBS) is a gastrointestinal
(GI) motility and sensory disorder characterized by
abdominal pain/discomfort, bloating, and altered
bowel habit, which determines the subtype classiﬁca-
tion: IBS with constipation (IBS-C), IBS with diarrhea
(IBS-D), or IBS with alternating bowel symptom
(IBS-A) [1–3]. IBS is a chronic condition and many
sufferers experience symptoms for 10 years or more.
The estimated symptom prevalence of IBS in Western
countries is 10% to 15%, with each IBS subtype occur-
ring at a similar frequency [1–5]. Considerable varia-
tion exists in the diagnosis rates of IBS. This is largely
due to inconsistent use of diagnostic guidelines [6] and
because more than one-third of sufferers fail to seek
medical advice [4].
Although typically not life-threatening, IBS causes
signiﬁcant impairment to sufferers’ quality of life
(QoL), affecting their daily routines, relationships,
social lives, and emotional well-being [4,5,7,8]. IBS
sufferers have signiﬁcantly more time off work than
nonsufferers [4,9], and IBS-related absenteeism and
reduced work productivity place a substantial eco-
nomic burden on employers [10].
Patients with IBS symptoms also utilize a signiﬁcant
amount of health-care resources. Although many
patients with IBS symptoms do not seek medical
advice, epidemiological studies show that IBS accounts
for approximately half of all visits to gastroenterolo-
gists in the United States and UK [11,12]. Also,
because of the chronic and complex nature of IBS
symptoms, many patients require a substantial amount
of outpatient and inpatient care, laboratory and radio-
logical tests [13].
Consequently, IBS is associated with a substantial
burden of illness because of its prevalence, morbidity,
and associated cost. Studies on the economic impact of
IBS estimated that direct costs for treating IBS patients
and indirect costs due to productivity loss/absenteeism
amount to $25 billion per year in the United States
[14–18]. It has been calculated that the yearly cost of a
patient with severe IBS is $2348 [19] in the UK and
€995 in Germany [20]. Overall, the economic impact
of IBS is comparable to that of other chronic and
episodic diseases, and its costs exceed those of asthma
and migraine [21–23].
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Traditional therapies for IBS, including antispas-
modics, laxatives, and antidiarrhea agents do not
provide adequate symptom relief for many patients as
they target only one of the multiple symptoms, and
may aggravate others [24–26]. Furthermore, their efﬁ-
cacy and safety have not been assessed by well-
designed, randomized controlled clinical trials [25,26].
In contrast, tegaserod, a 5-HT4 receptor partial
agonist and promotility agent, targets the multiple
symptoms of IBS-C. Tegaserod has been shown to
facilitate the peristaltic reﬂex, increase water move-
ment into the bowel lumen, and inhibit the visceral
afferent responses associated with abdominal pain
[27–29]. The efﬁcacy and safety of tegaserod have been
investigated in four key Phase III randomized, double-
blind, placebo-controlled trials involving almost 6000
IBS-C patients [30–33], including the Nordic region:
TEgaserod in NORdic region (TENOR) study [34].
Although the effect of tegaserod on patients’ QoL was
not routinely investigated [35], treatment has been
associated with improvements in patients’ QoL and
work productivity [33].
The objective of the current study was to assess
whether tegaserod is cost-effective in the treatment of
IBS patients. This analysis is based on the clinical
results from the TENOR study [34], which is repre-
sentative in its design and ﬁndings of other controlled
trials of tegaserod [30–33,35]. In an environment
where health-care resources are scarce, it is important
to demonstrate not only that a new product is safe and
efﬁcacious, but also that it offers value for money to
purchasers. Nevertheless, to date, only one published
article has assessed the cost-effectiveness of an agent
for IBS, speciﬁcally IBS-D (alosetron) [36]. To our
knowledge, this study is the ﬁrst analysis of the cost-
effectiveness of an agent designed to treat IBS-C.
Methods
Study Design
The economic evaluation of tegaserod was performed
with the data collected from the TENOR study, which
was a multinational, multicentre, double-blind, ran-
domized, placebo-controlled clinical trial conducted in
Nordic countries. Clinical results and patient enroll-
ment are described in detail elsewhere [34]. In brief,
the study consisted of a 2-week baseline period
without medication, a 12-week randomized double-
blind treatment period, followed by a 4-week with-
drawal period without medication. Patients were
not allowed to take medications affecting GI motility
and/or visceral perception, antiﬂatulence agents,
opioids/narcotic analgesics, prokinetics, anticholin-
ergics, antispasmodics, or antidepressants (except at
stable doses taken for indications other than IBS for at
least 3 months before commencement of the study).
Laxatives were permitted only as rescue medication.
A total of 647 patients were randomized to receive
either tegaserod 6 mg b.i.d. (327 patients) or placebo
(320 patients). The number of days of treatment with
tegaserod or placebo was recorded. Patients’ QoL/
utility was directly obtained in the study using the
EuroQol EQ-5D instrument for measuring patients’
health states at baseline [37,38], after 4 weeks, and
after 12 weeks or at discontinuation. The three EQ-5D
assessments were used subsequently for calculating the
gains in quality-adjusted life-year (QALY) in the study.
The QALY is an outcome measure that has the advan-
tage of combining the time (year) spent in different
health states with an estimate about the quality of this
time.
As the EQ-5D was only introduced as a study
amendment 6 months after the release of the trial pro-
tocol and after patient enrollment had started, only
75% of the patients were eligible to complete the
questionnaire.
Utility Estimates
Patient utilities were obtained from the EQ-5D ques-
tionnaire [37,38], which consists of two parts. In the
ﬁrst part (the health state description), patients answer
ﬁve questions on mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression (scored on a
3-point Likert scale). The ﬁrst part provides a classiﬁ-
cation of the patient’s health state, which can then be
valued according to “tariff” values. Tariff values are
derived from a sample of the general population in the
community, the most relevant population for public
policy analysis [39]. Well-established algorithms exist
for the transformation of the descriptive part of
EQ-5D to utility values [40]. The second part is a
visual analog scale (VAS), which is similar to a ther-
mometer marked from 0 (worst imaginable health
state) to 100 (best imaginable health). As the VAS
cannot be used to measure utility directly [41], utility
measures for this economic evaluation were obtained
from the ﬁrst part of the EQ-5D questionnaire (the
health state valuation). The EQ-5D is applicable to a
wide range of health conditions and treatments and
has been speciﬁcally validated for use in IBS patients
[42].
Economic Analysis
The incremental cost and the incremental utility gain
of tegaserod treatment vs. placebo over the 12-week
treatment period of the TENOR trial were compared
[34]. The perspective of the study was that of a third-
party pharmacy payer, based only on the cost of tega-
serod. Other costs, such as those associated with
patient visits, were not included in this analysis. The
cost per patient was calculated assuming that the cost
of tegaserod per treatment day was either €2, the
current public price of tegaserod in Switzerland, €3 or
€4. As it was assumed that patients receiving placebo
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represent untreated patients, the cost of drugs in the
placebo arm was set at zero. The time period of the
analysis was set at 12 weeks, because treatment and
follow-up data from TENOR are available for this
period [31].
The number of QALYs gained was estimated by
calculating the average gain in utility per patient from
the baseline period and over the 12-week period of the
study, based on EQ-5D health state scores derived
from the Health States Tariff evaluation. As the
average utilities for patients in the tegaserod and the
placebo groups differed at baseline, an analysis of
covariance (ANCOVA) regression controlling was per-
formed. The difference in baseline utilities between the
treatment and placebo groups may have been caused
by differences in underlying covariates, such as small
differences in age, sex, and country composition
between the two groups. Nevertheless, baseline utili-
ties and countries were the only covariates used for the
ANCOVA model as they were the only signiﬁcant
factors. For some reason, patients from Norway and
Finland reported signiﬁcantly higher utilities than did
patients from Denmark and Sweden. The utilities pre-
dicted by the regression model are those that would
have occurred had the baseline utilities been equal.
This method provides an unbiased estimation of dif-
ferential QALYs and a more precise estimate of its
variance [43–46]. There are some important reasons
why it is particularly important to control for baseline
utilities when estimating QALYs. The ﬁrst is that base-
line utilities usually enter directly into the QALY cal-
culation and thus strongly inﬂuence the number of
QALYs gained. The second is that the point estimate of
the incremental cost-effectiveness ratio (ICER) may be
sensitive to even a small imbalance in utilities between
the arms of the trial [47]. Nevertheless, the number of
QALYs gained per patient was also calculated with the
unadjusted baseline utility scores and the results of this
calculation will be described in the sensitivity analysis.
Missing data due to study withdrawals and non-
completion of the EQ-5D questionnaire were inter-
polated using the last-observation-carried-forward
(LOCF) method. In the sensitivity analysis, we also
tested what the results would be if patients with
missing data were excluded.
The number of QALYs for each patient was calcu-
lated as the area under the utility curve (AUC) from
baseline and over the 12-week period of the study.
Since the utility was only measured at baseline,
4 weeks and 12 weeks, it was assumed that it changed
linearly between measurements.
Bootstrap Analysis and Cost-Effectiveness
Acceptability Curves
The ICER of Treatment 1 (tegaserod) compared with
Treatment 0 (placebo) is deﬁned as ICER = DC/DE,
where ΔE E E= −1 0 is the difference in effect,
ΔC C C= −1 0 is the difference in drug costs. A well-
known problem with the cost-effectiveness ratio is its
unfavorable statistical properties that make it difﬁcult
to calculate conventional conﬁdence intervals. Thus,
cost-effectiveness acceptability curves have been
increasingly used to present the uncertainty of the cost-
effectiveness estimate in a way that overcomes the
problems associated with ICERs [48].
Nonparametric bootstrapping was used to estimate
the uncertainty of the cost-effectiveness estimate,
because the distribution of costs and QALY gains are
non-normal and skewed. Nonparametric bootstrap-
ping is a resampling technique useful for estimating
various statistics without using traditional parametric
formulas [49,50]. The basic principle of bootstrapping
is to use the available data sample for resampling with
replacement [50,51]. The resampling is performed
many times, and the size of each bootstrap resample is
the same as for the original sample.
In each round of resampling, cost and QALYs were
resampled for patients in the treatment and placebo
groups separately, and a bootstrap estimate of the
average QALY gain (for tegaserod and placebo
patients) and the average drug cost (for tegaserod
patients) was calculated. Then for each bootstrap rep-
lication, an ICER can be calculated. In total, 2000
bootstrap replications of the average QALY gain, the
average cost, and ICERs were calculated.
The cost-effectiveness acceptability curve is con-
structed by calculating the proportion of bootstrap
replications of the ICER that is acceptable at different
levels of willingness to pay per QALY, and determined
by the slope of the line passing through the origin on
the cost-effectiveness plane.
A sensitivity analysis was performed using the
unadjusted baseline EQ-5D utility scores, and the
ICERs and cost-effectiveness acceptability curves were
also calculated [52].
Results
Population Enrolled in the Health-Economic Analysis
A total of 485 out of 644 patients (75% of patients
randomized in the TENOR study) were eligible to
answer the EQ-5D questionnaire; 247 (75.5%) in the
tegaserod group and 238 (74.4%) in the placebo
group. The demographic and disease background
information presented in Table 1 shows that there
were no clinically important differences between
patients randomized in the double-blind treatment
period and patients eligible to complete the EQ-5D
questionnaire.
Treatment Cost
The mean number of treatment days was calculated for
both the tegaserod and placebo groups. The patients
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received treatment for on average 73.1 days in the
tegaserod group, and 77.0 days in the placebo group.
The cost of tegaserod treatment was calculated by
multiplying the treatment duration in days by the cost
per day. As mentioned previously, the placebo arm was
treated as a proxy for no treatment, with no costs
incurred.
EQ-5D Scores
EQ-5D average baseline utilities were 0.713 in the
tegaserod group and 0.740 in the placebo group
before adjustment with the ANCOVA regression
model. At Week 4, average utilities were 0.791 and
0.766, respectively, for the tegaserod and the placebo
groups, and at Week 12, 0.787 in the tegaserod group
and 0.753 in the placebo group. The adjusted average
utility scores obtained using the regression model
were 0.726 at baseline for both the tegaserod and the
placebo groups. At Week 4, the adjusted utilities were
0.7954 for patients receiving tegaserod and 0.7587
for placebo-treated patients, and at Week 12 utilities
were 0.7915 and 0.7468 for the tegaserod and the
placebo groups, respectively. As highlighted in
Table 2, the change from baseline to Week 4 was
0.0694 for the tegaserod group and 0.0327 for the
placebo group (P = 0.036), and from baseline to
Week 12 the change was 0.0655 and 0.0207 for
the tegaserod and the placebo groups (P = 0.023),
respectively.
Base-Case Analysis
The incremental average gain in QALYs can be calcu-
lated as the difference in AUC between placebo and
tegaserod, which is represented by the shaded area
in Figure 1. The incremental gain in QALYs with
adjusted utilities for the tegaserod group over
the placebo group was equal to 0.0077. [4/52 ¥
(0.726 + 0.7954)/2 + 8/52 ¥ (0.7954 +0.7915)/2 - 4/
52 ¥ (0.726 + 0.7587)/2 - 8/52 ¥ (0.7587 + 0.7468)/2].
With a daily tegaserod cost of €2, the average cost
in the treatment group was €73.14 ¥ 2 = €146.3, and
the ICER of tegaserod was €146.3/0.0077 = €19,000
per QALY gained. The ICERs calculated, as above,
with a daily treatment cost of €3 and €4 were €28,500
and €38,000, respectively, per QALY gained. All these
ICER values are below the €50,000 per QALY gained,
which is the threshold commonly used to assess
whether or not an intervention can be considered
cost-effective [53].
Table 1 Demographic and disease background information
comparison between patients who ﬁlled out the health economic
questionnaire (n = 485) and the intent-to-treat population
(n = 644)
Total trial
population
n = 644
Total HE
population
n = 485 P-value*†
Sex: n (%)
Male 91 (14.1) 70 (14.4)
Female 553 (85.9) 415 (85.6) 0.8856*
Race: n (%)
Caucasian 641 (99.5) 483 (99.6)
Asian 2 (0.3) 1 (0.2)
Other 1 (0.2) 1 (0.2) 1.0000*
Age (years)
Mean SD 44.3 12.1 44.4 12.3
Range 18–65 19–65 0.8586†
Weight (kg)
Mean SD 69.6 13.5 69.6 13.1
Range 34–143 34–134 0.9971†
Duration of IBS
symptoms (months)
Mean SD 204.1 161.4 211.7 165.1
Range 12–720 12–720 0.4407†
Prior drug treatment
for IBS symptoms‡:
n (%)
No 383 (80.6) 377 (80.4)
Yes 92 (19.4) 92 (19.6) 0.9234*
*Chi-squared test performed for signiﬁcance test.
†t-test performed for signiﬁcance test.
‡Only variable MEDTAK1C used to assess prior drug treatment for IBS symptoms.
HE, health economic; IBS, irritable bowel syndrome.
Table 2 EQ-5D utility score (LOCF) ﬁtting an ANCOVA model (n = 485)
Time
Tegaserod Placebo
P-value*Actual
Change from
baseline Actual
Change from
baseline
Baseline
n 247 238
Mean 0.726 0.726
SD 0.248 0.224
Visit 3 (Week 4)
n 247 238
Mean 0.7954 0.0694 0.7587 0.0327 0.036
SD 0.200 0.242 0.207 0.203
Visit 4 (Week 12)
n 247 238
Mean 0.7915 0.0655 0.7468 0.0207 0.023
SD 0.214 0.247 0.244 0.245
Number of days in the treatment 73.1 77.0
*ANCOVA controlling for baseline utility and country.
LOCF, last observation carried forward.
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Cost-Effectiveness Acceptability Curves
A cost-effectiveness acceptability curve provides an
estimate of the sampling distribution of costs and
effects that lie below the price that corresponds to the
maximum willingness to pay for a gained effect unit,
the price line in the graph [54–56]. Figure 2 illustrates
the cost-effectiveness acceptability curves for tegaserod
with daily treatment costs ranging from €2 to €4 per
day. At a daily cost of €2, nearly 90% of the bootstrap
cost-effectiveness estimates fall within a benchmark
value for cost-effectiveness of €50,000. For the higher
tegaserod prices of €3 and €4 per day, the percentage of
estimates below the threshold of €50,000 per QALY
gained were 81% and 69%, respectively.
Sensitivity Analysis
The results of the sensitivity analysis performed using
the unadjusted utilities show that the incremental gain
in QALYs for the tegaserod group over the placebo
group was equal to 0.0108. [4/52 ¥ (0.7125 +
0.7913)/2 + 8/52 ¥ (0.7913 + 0.7872)/2 - 12 ¥
0.7125/52 - 4/52 ¥ (0.7399 + 0.7657)/2 - 8/52 ¥
(0.7657 + 0.7532)/2 + 12 ¥ 0.7399/52]
With a daily tegaserod cost of €2, the average cost
in the treatment group was €73.14 ¥ 2 = €146.3, and
the ICER of tegaserod was €146.3/0.0108 = €13,500
per QALY gained. The ICERs calculated with a daily
treatment cost of €3 and €4 were €20,200 and
€27,000, respectively, per QALY gained. These ICER
values are below those that were based on adjusted
utility values.
The cost-effectiveness acceptability curves of the
sensitivity analysis using unadjusted utilities for a tega-
serod daily treatment cost ranging from €2 to €4 per
day are illustrated in Figure 3. At the daily treatment
cost of €2 per day, 98% of the bootstrap cost-
effectiveness estimates are below the threshold of
€50,000 per QALY. At the higher tegaserod cost of €3
and €4 per day, the percentage of bootstrap estimates
below the threshold was 95% and 90%, respectively.
All these percentages are above those calculated in the
base-case analysis.
If only women are included in the analysis, the
ICERs fall in the range of €20,700 to €41,400, for a
tegaserod price of €2, €3, and €4, respectively. If only
men are included, the ICERs fall in the range of
€12,800 to €25,600.
0.82
0.8
0.78
0.76
0.74
0.72
0.726
0.7954
0.7587
0.7468
0.7915
Tegaserod
Placebo
Gain in QALYs for tegaserod patients
0.7
0.68
(B
as
eli
ne
) 0
(V
isi
t 3
) W
ee
k 4
(V
isi
t 4
) W
ee
k 1
21 2 3 5 6 7 8 9 10 11 Figure 1 Utility levels and gain in quality-
adjusted life-years with tegaserod compared
with placebo with adjusted baseline utility
scores.
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0
Willingness to Pay (EUR)
C
o
st
-e
ff
ec
ti
ve
n
es
s 
A
cc
ep
ta
b
ili
ty
€3
€4
€2
200,000150,000100,00050,000
Figure 2 Base-case analysis: cost-effectiveness
acceptability curves for tegaserod at a daily cost
of 2€, 3€, and 4€.
242 Bracco et al.
Some utilities were extrapolated based on the
LOCF principle. If we repeat the calculation above
with only the patients with complete utility measure-
ments included, then the average QALY gain would be
0.013, and the cost-effectiveness ratios would be
€11,300 for a daily tegaserod cost of €2, €16,900 for a
daily tegaserod cost of €3, and €22,500 for a daily
tegaserod cost of €4. This shows that the inclusion of
LOCF utilities did not introduce any upward bias in
favor of the treatment group.
Discussion
Irritable bowel syndrome is a chronic disease with high
reported symptom prevalence in Western populations,
but no new agent speciﬁc to IBS has been introduced in
Europe in decades. In previous clinical trials, tegaserod
has proved to be an effective and well-tolerated treat-
ment for abdominal pain, bloating, and constipation,
which are the most common symptoms of IBS
[30–34,57,58]. Nevertheless, no published study has
yet reported on the cost-effectiveness of tegaserod.
In this study, treatment costs and utility data from
the EQ-5D questionnaire were collected prospectively
in a randomized, placebo-controlled clinical trial and
combined to assess the cost-effectiveness of tegaserod
in the treatment of patients with non-IBS-D. An advan-
tage of a generalized outcome measure like QALY is
that it allows comparison of interventions within and
across therapeutic areas in terms of cost per QALY
gained [56].
The base-case economic analysis of this study estab-
lished that the ICERs for tegaserod calculated at the
daily treatment costs of €2, €3, and €4, fall in the range
of €19,000 to €38,000 per QALY gained with a prob-
ability of being cost-effective at a threshold of €50,000
per QALY gained ranging between 90% and 69%.
The ICERs calculated in the sensitivity analysis,
performed with unadjusted baseline utility scores and
calculated with the same tegaserod treatment costs,
range between €13,500 and €27,000 per QALY
gained. These values are much lower than those calcu-
lated in the base-case analysis. The cost-effectiveness
acceptability curves calculated in the sensitivity analy-
sis show that the percentages of estimates below the
threshold of €50,000 per QALY gained fall between
98% and 90%.
The current study, however, had some limitations. It
only included the drug cost for tegaserod, but not
associated IBS medical costs. Thus, potential medical
cost-offsets with tegaserod, such as the cost reduction
of extra medical and diagnostic visits, hospitalizations,
and concomitant treatments often used by IBS patients
to treat the multiple symptoms of the condition, were
not taken into account. Furthermore, in this economic
analysis, indirect costs were not included as these data
were not collected in the TENOR trial. Nevertheless,
the results of a recent multinational clinical trial in
IBS-C patients showed that tegaserod reduced produc-
tivity loss compared with placebo [59]. Additionally, a
retrospective assessment of GI-related resource use in a
managed care setting in the United States showed that
tegaserod was associated with consistent and sig-
niﬁcant decreases in most resource categories [60].
Therefore, inclusion of these factors would probably
only reinforce the conclusion that tegaserod is cost-
effective.
This study is an economic analysis using data
collecting in a randomized placebo controlled trial.
Although the cost-effectiveness of tegaserod vs. an
alternative active treatment would be more relevant
for health-care decision-makers, tegaserod is currently
the only drug approved for IBS with constipation. A
comparison of tegaserod with an active treatment is
currently not possible or relevant.
Since this study is based on a randomized controlled
trial, one limitation is the validity of these results in the
real-world clinical practice. The follow-up time was
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quite short, for example. Our results regarding costs
and QALY are only valid for the 12-week time frame
used in the study. If the results would be similar for
long-term evaluation of tegaserod is an issue for
further research.
In the United States, however, where it has been on
the market since 2002, tegaserod is indicated for the
short-term treatment of women with IBS-C. Thus,
there is reason to believe that the time frame of this
analysis reﬂects the recommended use of the drug. In
the TENOR trial, male patients, for whom the drug is
not recommended, were enrolled in the study. Never-
theless, as presented in the sensitivity analysis, if the
male population is excluded, the results are little worse
but the difference compared with the base-case results
is small.
It should be also mentioned that the threshold of
€50,000 per QALY used in this study is primarily
based on a rule of thumb. In practice, the willingness
to pay per QALY could very well vary depending on
the nature of the disease, and the duration of symp-
toms. Whether the €50,000 threshold is the most
appropriate in our study is uncertain, but we used it in
the absence of better information regarding the soci-
etal willingness to pay for treating patients with IBS.
Conclusions
An extensive clinical trial program has established that
tegaserod is currently the only effective and well-
tolerated treatment for abdominal pain, bloating,
and constipation in IBS patients without diarrhea
[30–34,57,58]. This analysis demonstrates that tegas-
erod is also a cost-effective treatment for patients with
IBS.
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